title: Use of enoxaparin in end-stage renal disease.
abstract: Enoxaparin has become the treatment of choice for various thromboembolic diseases. In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens. Empirical dose adjustment and biological monitoring seem to be necessary along with therapeutic doses. Anti-factor Xa poorly predicts the degree of anticoagulation in ESRD patients given enoxaparin.
authors.affiliation: Department of Clinical Medicine, Sapienza, University of Rome, Rome, Italy. silvia.lai@uniroma1.it
authors.forename: Silvia
authors.initials: S
authors.lastname: Lai
authors.forename: Bettina
authors.initials: B
authors.lastname: Coppola
mesh_terms: D017984:Enoxaparin / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000453:epidemiology*; D006493:Heparin / Q000008:administration & dosage* / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D054556:Venous Thromboembolism / Q000517:prevention & control*
chemical_list: D017984:Enoxaparin; D006493:Heparin